IDO-Independent Suppression of T Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Human bone marrow–derived mesenchymal stromal cells (MSCs) inhibit proliferation of activated T cells, and IFN-γ plays an important role in this process. This IFN-γ–licensed veto property is IDO-dependent. To further decipher the mechanistic underpinnings of MSC veto function on T cells, we investigated the effect of MSCs and IFN-γ–licensed MSCs on T cell effector function as assayed by cytokine secretion of T cells. Although MSCs and IFN-γ–licensed MSCs inhibit T cell proliferation, only IFN-γ–licensed MSCs significantly inhibit Th1 cytokine (IFN-γ, TNF-α, and IL-2) production by T cells. Additionally, IFN-γ–licensed MSCs inhibit T cell degranulation as well as single, double, and triple cytokine–producing T cells. Although IFN-γ–licensed MSCs upregulate their IDO activity, we found that MSC IDO catalytic function is dispensable with regard to MSC-driven inhibition of T cell effector function. Novel flow cytometry based functional screening of MSC-expressed, IFN-γ–licensed inhibitory molecules identified B7H1 and B7DC/PD1 pathways as essential effectors in blocking T cell function. Small interfering RNA–mediated blocking of B7H1 and B7DC reverses the inhibitory potential of IFN-γ–licensed MSCs on T cell effector function. Mechanistic analysis revealed that clustering of MHC and coinhibitory molecules are indispensable for the inhibitory effect of IFN-γ MSCs. Although exogenous IL-2 reverses B7H1-Ig–mediated inhibition of T cell proliferation, it does not affect the veto function of IFN-γ MSCs on both T cell proliferation and effector function. Our results reveal a new immunosuppressive property of IFN-γ–licensed MSCs that inhibits T cell effector function independent of IDO but through the ligands for PD1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study by Chinnadurai et al. elegantly showed that MSCs can inhibit PBMC proliferation through PD1/PD-L1 [48].”
In the citing paper
“IFN-γ-primed MSCs have demonstrated to block T cell proliferation in a dose-dependent manner and to abrogate the production of IFN-γ, IL-2 and TNF-α, three cytokines with a role in T cell-derived immune response [136].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [136]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“M arrowmesenchymal stromal cells (MSCs) play a role in maintaining the hematopoietic niche, regulate marrow immune homeostasis, and can differentiate into bone, cartilage, and adipocytes as a mesenchymal progenitor pool (1, 2).”
BackgroundMesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746 · cited 1×
“The therapeutic potential of transfused MSCs has been demonstrated in animal models of experimental autoimmune encephalitis, diabetes, rheumatoid arthritis, myocardial infarction, acute lung injury, retinal degeneration, acute renal failure, and transplant rejection (9, 10).”
BackgroundDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226 · cited 1×
“Therefore, an analysis of MSC immune plasticity in response to exogenous IFN-g stimulation (6, 22) and how this serves as an immune checkpoint to T cell activity are of physiological and translational interest.”
MethodCentral Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067 · cited 1×
“Once naive T cells are exposed to an activation signal they proliferate, and a subset becomes effector T cells as manifested by cytokine secretion and degranulation, based on their memory status (23, 24).”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734 · cited 1×
“In human phase II clinical trials, MSCs were shown to be effective in treating graft-versus-host disease (11), although study of an industrial MSC product in a phase III trial was negative (12–14).”
BackgroundFriedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970) · Cell Proliferation · doi:10.1111/j.1365-2184.1970.tb00347.x · Cited by 2,724 · cited 1×
“Although endogenous clonogenic marrow MSCs represent a small minority of all nucleated cells in marrow space, typically 1:100,000, these same cells possess a robust mitogenic potential when cultured ex vivo (3, 4).”
BackgroundThe Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundHeterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.
Friedenstein, A. J., Kv, P., KUROLESOVA, A. I., & Frolova, G. P. (1968) · PubMed · Cited by 1,921
HETEROTOPIC TRANSPLANTS OF BONE MARROW
FRIEDENSTEIN, A. J., PETRAKOVA, K. V., KUROLESOVA, A. I., & FROLOVA, G. P. (1968) · Transplantation · doi:10.1097/00007890-196803000-00009 · Cited by 1,699
Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Krampera, M., Glennie, S., Dyson, J., Scott, D., Laylor, R., Simpson, E., & Dazzi, F. (2003) · Blood · doi:10.1182/blood-2002-07-2104 · Cited by 1,598
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528 · cited 1×
“It is well known that B7H1 and B7DC inhibit the proliferation of PD1 T cells (43), and IFN-g– licensed mouse MSCs have been shown previously to inhibit T cell proliferation through B7H1 (44, 45).”
BackgroundTse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C., & Guinan, E. C. (2003) · Transplantation · doi:10.1097/01.tp.0000045055.63901.a9 · Cited by 1,500
Role for Interferon-γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells
Krampera, M., Cosmi, L., Angeli, R., Pasini, A., Liotta, F., Andreini, A., Santarlasci, V., Mazzinghi, B., Pizzolo, G., Vinante, F., et al. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0008 · Cited by 1,311
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 1×
“(55) described that PD1 engagement with its ligand, PDL1, causes the clustering of PD1 and FIGURE 6.”
BackgroundBone marrow mesenchymal stem cells induce division arrest anergy of activated T cells
Glennie, S., Soeiro, I., Dyson, P. J., Lam, E. W.-F., & Dazzi, F. (2005) · Blood · doi:10.1182/blood-2004-09-3696 · Cited by 1,150
Multipotent mesenchymal stromal cells and the innate immune system
Le Blanc, K., & Mougiakakos, D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3209 · Cited by 1,018 · cited 1×
“These data add to a growing body of knowledge examining the immune plasticity of MSCs and their veto function (46).”
BackgroundIL-6 switches the differentiation of monocytes from dendritic cells to macrophages
Chomarat, P., Banchereau, J., Davoust, J., & Karolina Palucka, A. (2000) · Nature Immunology · doi:10.1038/82763 · Cited by 906 · cited 1×
“Additionally, MSC-derived IL-6 will promote regeneration of radiation-injured gut epithelium and has been suggested to play an important role in converting monocytes to suppressor macrophages (49, 50).”
BackgroundCharacterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny
Castro-Malaspina, H., Gay, R., Resnick, G., Kapoor, N., Meyers, P., Chiarieri, D., McKenzie, S., Broxmeyer, H., & Moore, M. (1980) · Blood · doi:10.1182/blood.v56.2.289.289 · Cited by 852 · cited 1×
“Although endogenous clonogenic marrow MSCs represent a small minority of all nucleated cells in marrow space, typically 1:100,000, these same cells possess a robust mitogenic potential when cultured ex vivo (3, 4).”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Superantigens: Mechanism Of T Cell Stimulation And Role In Immune-Responses
Herman, A. (1991) · Annual Review of Immunology · doi:10.1146/annurev.immunol.9.1.745 · Cited by 794 · cited 4×
“We have used the superantigen SEB to stimulate T cells as a surrogate system that mimics the physiological activation of Agspecific T cells by MHC and TCR engagement in an effort to gain novel insights complementary to in vitro observations made with responder T cells pharmacologically activated with anti-CD3 or PMA/i…”
BackgroundMethodInfluentialMesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell Apoptosis
Akiyama, K., Chen, C., Wang, D., Xu, X., Qu, C., Yamaza, T., Cai, T., Chen, W., Sun, L., & Shi, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.03.007 · Cited by 705 · cited 2×
“Considering the published report on the role of MSCs in inducing T cell apoptosis by CD95L, the regulation of its surface expression on MSCs needs to be studied in the future (42).”
BackgroundFrançois, M., Romieu-Mourez, R., Li, M., & Galipeau, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.189 · Cited by 694 · cited 4×
“We and others had shown that human MSC suppression of T cell proliferation is dependent on IDO induction and catalytic activity (8, 22).”
BackgroundMethodInfluentialSelf-citationPD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
Carter, L. L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M., Honjo, T., Freeman, G. J., & Carreno, B. M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9 · Cited by 673 · cited 1×
“Previous studies have shown that addition of IL-2 overcomes B7H1-mediated inhibition of T cell proliferation (28).”
BackgroundLiu, Y., Wang, L., Kikuiri, T., Akiyama, K., Chen, C., Xu, X., Yang, R., Chen, W., Wang, S., & Shi, S. (2011) · Nature Medicine · doi:10.1038/nm.2542 · Cited by 655
Ghannam, S., Pène, J., Torcy-Moquet, G., Jorgensen, C., & Yssel, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902007 · Cited by 597
Ryan, J. M., Barry, F., Murphy, J. M., & Mahon, B. P. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03422.x · Cited by 596
Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
Croft, M. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101243 · Cited by 548 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundGalipeau, J. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2012.10.002 · Cited by 448 · cited 2×
“Although host factors, source, and functionality of MSCs may contribute to inconsistent outcomes of clinical trials, a better understanding of cellular immunology of MSCs would help to optimize and possibly enhance the pharmaceutical utility of such cells (13, 16).”
BackgroundSelf-citationIFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells
English, K., Barry, F. P., Field-Corbett, C. P., & Mahon, B. P. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.04.001 · Cited by 415
Nemeth, K., Keane-Myers, A., Brown, J. M., Metcalfe, D. D., Gorham, J. D., Bundoc, V. G., Hodges, M. G., Jelinek, I., Madala, S., Karpati, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910720107 · Cited by 408 · cited 1×
“IL-10 is never expressed by MSCs and it is not augmented by cytokine licensing (22, 54).”
BackgroundSheng, H., Wang, Y., Jin, Y., Zhang, Q., Zhang, Y., Wang, L., Shen, B., Yin, S., Liu, W., Cui, L., et al. (2008) · Cell Research · doi:10.1038/cr.2008.80 · Cited by 388 · cited 1×
“It is well known that B7H1 and B7DC inhibit the proliferation of PD1 T cells (43), and IFN-g– licensed mouse MSCs have been shown previously to inhibit T cell proliferation through B7H1 (44, 45).”
BackgroundRafei, M., Campeau, P. M., Aguilar-Mahecha, A., Buchanan, M., Williams, P., Birman, E., Yuan, S., Young, Y. K., Boivin, M.-N., Forner, K., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803962 · Cited by 381
Self-citationPatel, S. A., Meyer, J. R., Greco, S. J., Corcoran, K. E., Bryan, M., & Rameshwar, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903143 · Cited by 363
Self-citationCD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator
Cai, G., Anumanthan, A., Brown, J. A., Greenfield, E. A., Zhu, B., & Freeman, G. J. (2008) · Nature Immunology · doi:10.1038/ni1554 · Cited by 345 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundDuijvestein, M., Wildenberg, M. E., Welling, M. M., Hennink, S., Molendijk, I., van Zuylen, V. L., Bosse, T., Vos, A. C. W., de Jonge-Muller, E. S. M., Roelofs, H., et al. (2011) · Stem Cells · doi:10.1002/stem.698 · Cited by 330 · cited 1×
“By considering the combinatorial IFN-g–licensed direct effect of MSCs on T cell proliferation, effector function, and the indirect effect on T cell proliferation through soluble factors, we predict that IFN-g–prelicensed autologous MSCs would generate a more potent and primed cell therapy product for suppression of im…”
BackgroundConcise Review: Mesenchymal Stem Cells and Translational Medicine: Emerging Issues
Ren, G., Chen, X., Dong, F., Li, W., Ren, X., Zhang, Y., & Shi, Y. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2011-0019 · Cited by 307
Romieu-Mourez, R., François, M., Boivin, M.-N., Bouchentouf, M., Spaner, D. E., & Galipeau, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803864 · Cited by 299
Self-citationInterferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell
Stagg, J., Pommey, S., Eliopoulos, N., & Galipeau, J. (2006) · Blood · doi:10.1182/blood-2005-07-2793 · Cited by 290 · cited 2×
“On day 4, cells were trypsinized and subjected to flow cytometry analysis of expression of HLA-ABC, HLA-DR, CD80, CD86, B7H1, B7DC, CD95L, and appropriate isotype controls (BD Biosciences).”
ResultSelf-citationCroitoru-Lamoury, J., Lamoury, F. M. J., Caristo, M., Suzuki, K., Walker, D., Takikawa, O., Taylor, R., & Brew, B. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014698 · Cited by 226 · cited 3×
“On day 4, cells were trypsinized and subjected to flow cytometry analysis of expression of HLA-ABC, HLA-DR, CD80, CD86, B7H1, B7DC, CD95L, and appropriate isotype controls (BD Biosciences).”
BackgroundResultRafei, M., Hsieh, J., Fortier, S., Li, M., Yuan, S., Birman, E., Forner, K., Boivin, M.-N., Doody, K., Tremblay, M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-166892 · Cited by 224 · cited 1×
“Although counterintuitive, the CCL2 expressed by MSCs is subjected to partial N-terminal cleavage converting CCL2 to an antagonist with profound inhibitory effects on Th17 cells and immunoblasts as well (47, 48).”
BackgroundSelf-citationTipnis, S., Viswanathan, C., & Majumdar, A. S. (2010) · Immunology & Cell Biology · doi:10.1038/icb.2010.47 · Cited by 218 · cited 1×
“It is well known that B7H1 and B7DC inhibit the proliferation of PD1 T cells (43), and IFN-g– licensed mouse MSCs have been shown previously to inhibit T cell proliferation through B7H1 (44, 45).”
BackgroundRamasamy, R., Tong, C. K., Seow, H. F., Vidyadaran, S., & Dazzi, F. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2008.04.009 · Cited by 191 · cited 2×
“Discussion Previous studies have found that unlicensed MSCs solely block mitogen-driven T cell proliferation and do not inhibit the effector functions of T cells (25, 29).”
BackgroundLiu, Y., Han, Z.-P., Zhang, S.-S., Jing, Y.-Y., Bu, X.-X., Wang, C.-Y., Sun, K., Jiang, G.-C., Zhao, X., Li, R., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213108 · Cited by 187 · cited 1×
“These observations may inform a strategy targeting tumor microenvironment as part of a cancer immunotherapy strategy where contemporaneous PD1 and IDO blockade may be required for optimally overcoming immune escape mechanisms by tumor cloaked in host-derived stromal cells (59, 60).”
BackgroundDifferentiation of memory B and T cells
Kalia, V., Sarkar, S., Gourley, T. S., Rouse, B. T., & Ahmed, R. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.03.020 · Cited by 186 · cited 1×
“Once naive T cells are exposed to an activation signal they proliferate, and a subset becomes effector T cells as manifested by cytokine secretion and degranulation, based on their memory status (23, 24).”
BackgroundMartin, P. J., Uberti, J. P., Soiffer, R. J., Klingemann, H., Waller, E. K., Daly, A. S., Herrmann, R. P., & Kebriaei, P. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.12.057 · Cited by 176
Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
Karlsson, H., Samarasinghe, S., Ball, L. M., Sundberg, B., Lankester, A. C., Dazzi, F., Uzunel, M., Rao, K., Veys, P., Le Blanc, K., et al. (2008) · Blood · doi:10.1182/blood-2007-10-119370 · Cited by 164 · cited 1×
“Discussion Previous studies have found that unlicensed MSCs solely block mitogen-driven T cell proliferation and do not inhibit the effector functions of T cells (25, 29).”
BackgroundWells, A. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803917 · Cited by 153 · cited 1×
“T cell anergy can be reversed by exogenous IL-2, and we tested whether environmental IL-2 will mitigate the inhibitory effect of MSCs on T cells (56).”
BackgroundMolecular Basis of the Dual Functions of 2B4 (CD244)
Chlewicki, L. K., Velikovsky, C. A., Balakrishnan, V., Mariuzza, R. A., & Kumar, V. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8159 · Cited by 150
HLA-G is a Crucial Immunosuppressive Molecule Secreted by Adult Human Mesenchymal Stem Cells
Selmani, Z., Naji, A., Gaiffe, E., Obert, L., Tiberghien, P., Rouas-Freiss, N., Carosella, E. D., & Deschaseaux, F. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a2a4b3 · Cited by 150 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundMesenchymal stem cells and autoimmune diseases
Dazzi, F., & Krampera, M. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.01.002 · Cited by 143
Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling
Shui, J.-W., Steinberg, M. W., & Kronenberg, M. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0910528 · Cited by 109 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundGenzyme backs Osiris, despite Prochymal flop
Allison, M. (2009) · Nature Biotechnology · doi:10.1038/nbt1109-966 · Cited by 107
Gieseke, F., Schütt, B., Viebahn, S., Koscielniak, E., Friedrich, W., Handgretinger, R., & Müller, I. (2007) · Blood · doi:10.1182/blood-2007-04-083162 · Cited by 105 · cited 1×
“There are now numerous suppressor pathways suggested to be operative in human MSCs distinct to IFN-g–augmented IDO catalytic activity cells (32, 33), and we tested which among these were augmented by IFN-g licensing.”
MethodHuman T cells from autoimmune and normal individuals can produce tumor necrosis factor
Turner, M., Londei, M., & Feldmann, M. (1987) · European Journal of Immunology · doi:10.1002/eji.1830171220 · Cited by 92 · cited 1×
“The inhibitory potential of IFN-g–licensed MSCs on the highly inflammatory TNF-a–producing T cells we observed is of significant interest because this T cell effector subset may be associated with the pathogenesis of autoimmune disorders amenable to MSC cellular therapies (62).”
BackgroundTHE TWO-SIGNAL MODEL OF T-CELL ACTIVATION AFTER 30 YEARS
Bernard, A., Lamy, L., & Alberti, I. (2002) · Transplantation · doi:10.1097/00007890-200201151-00011 · Cited by 90
Costello, R. T., Mallet, F., Sainty, D., Maraninchi, D., Gastaut, J.-A., & Olive, D. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199801)28:01<90::aid-immu90>3.0.co;2-5 · Cited by 81
Ren, J., Jin, P., Sabatino, M., Balakumaran, A., Feng, J., Kuznetsov, S. A., Klein, H. G., Robey, P. G., & Stroncek, D. F. (2011) · Cytotherapy · doi:10.3109/14653249.2010.548379 · Cited by 72 · cited 1×
“Culture-expanded bone marrow–derived MSCs possess a unique transcriptome that distinguishes them from fibroblasts and hematopoietic stem cells, and these cells retain cell physiological properties that likely reflect the innate biological functions of the clonal marrow-nested progenitors from which they arose (57).”
BackgroundHolmannová, D., Koláčková, M., Kondělková, K., Kuneš, P., Krejsek, J., & Andrýs, C. (2012) · Acta Medica (Hradec Kralove, Czech Republic) · doi:10.14712/18059694.2015.68 · Cited by 67 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundDeath and inflammation following somatic cell transplantation
Copland, I. B., & Galipeau, J. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0274-8 · Cited by 49 · cited 1×
“200 clinical trials are registered to test the use of MSCs to treat targeted immune-related disorders (multiple sclerosis, graft-versus-host disease, Crohn’s disease) and cardiovascular conditions (myocardial infarction, ischemia) (15).”
BackgroundSelf-citationNew insights on translational development of mesenchymal stromal cells for suppressor therapy
François, M., & Galipeau, J. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24081 · Cited by 40 · cited 2×
“Although host factors, source, and functionality of MSCs may contribute to inconsistent outcomes of clinical trials, a better understanding of cellular immunology of MSCs would help to optimize and possibly enhance the pharmaceutical utility of such cells (13, 16).”
BackgroundSelf-citationA new therapeutic strategy for malaria: targeting T cell exhaustion
Freeman, G. J., & Sharpe, A. H. (2012) · Nature Immunology · doi:10.1038/ni.2211 · Cited by 36 · cited 7×
“To identify contact-dependent MSC inhibitory pathways, we employed a flow cytometry–based functional screening approach interrogating candidate cell surface effectors based on published literature (26).”
BackgroundMethodInfluentialFrançois, M., Birman, E., Forner, K.-A., Gaboury, L. A., & Galipeau, J. (2012) · Cytotherapy · doi:10.3109/14653249.2012.684378 · Cited by 26
Self-citation
Research works printed but not linked: 1
- Jeremias, 1998, TRAIL/Apo-2-ligand-induced apoptosis in human T cells, Eur. J. Immunol., 28, 143, 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3 · DOI · Paper page
Cited by
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
Immune modulation by mesenchymal stem cells
Jiang, W., & Xu, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12712 · Cited by 650
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies
Noronha, N. D. C., Mizukami, A., Caliári-Oliveira, C., Cominal, J. G., Rocha, J. L. M., Covas, D. T., Swiech, K., & Malmegrim, K. C. R. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1224-y · Cited by 623
“functions through the upregulation of programmed cell death-1 ligands (PDL-1), at the same time, but independently of IDO upregulation [20].”
BackgroundGalipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R. J., DeBruijn, J., Dominici, M., Fibbe, W. E., Gee, A. P., Gimble, J. M., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2015.11.008 · Cited by 520
Self-citation
Metadata
- Authors
- Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J.
- Affiliations
- Emory University (US)
- Corresponding author
- Chinnadurai, Raghavan
- Galipeau, Jacques
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02
- Volume
- 192
- Issue
- 4
- Pages
- 1491-1501
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147854121
- Cited by
- 266
- References
- 63
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 15 · 2023: 30 · 2022: 15 · 2021: 28 · 2020: 31 · 2019: 19 · 2018: 22 · 2017: 25 · 2016: 24 · 2015: 21 · 2014: 10
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (T32AI007610)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- mesenchymal stem cells, T cell effector function, PD-L1, PD-1, T cell degranulation, interleukin-2, T cell proliferation inhibition, bone marrow-derived stromal cells
- MeSH terms
- Bone Marrow Cells, Cells, Cultured, Humans, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Tumor Necrosis Factor-alpha, Cell Degranulation, Th1 Cells, RNA Interference, RNA, Small Interfering, Cell Proliferation, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mesenchymal Stem Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.